Ting S.
About Ting S.
Ting S. is the Director of Intellectual Property at Brii Biosciences, where they manage outside counsel and conduct IP due diligence. With a strong background in organic and medicinal chemistry, Ting has authored numerous publications and holds nine issued US patents.
Work at Brii Biosciences
Ting S. has been serving as the Director of Intellectual Property at Brii Biosciences since 2021. In this role, Ting manages outside counsel and conducts intellectual property due diligence. This position involves overseeing the development and implementation of intellectual property strategies that align with the company's goals in the biopharmaceutical sector.
Previous Experience in Intellectual Property
Prior to joining Brii Biosciences, Ting S. worked at Portola Pharmaceuticals as Director of Intellectual Property from 2005 to 2020. In this capacity, Ting was responsible for managing global patent portfolios and developing strategies for intellectual property protection. Additionally, Ting held the position of Patent Agent at Novartis from 2003 to 2005, where they contributed to patent-related activities in the San Francisco Bay Area.
Education and Expertise
Ting S. holds a Ph.D. in Organic/Medicinal Chemistry from the University of Illinois at Chicago. They also earned a Bachelor of Science in Organic Chemistry from Wuhan University and completed a postdoctoral program in Biochemistry at Northwestern University. This educational background provides a strong foundation for their expertise in intellectual property within the biopharmaceutical industry.
Achievements in Patents and Publications
Ting S. is an inventor of nine issued US patents, showcasing a significant contribution to the field of intellectual property. Additionally, they have authored 19 publications and delivered 15 presentations at various meetings, reflecting a commitment to advancing knowledge in their area of expertise.
Background in Pharmaceutical Industry
Ting S. has extensive experience in the pharmaceutical industry, having worked at Millennium Pharmaceuticals as a Senior Scientist from 1992 to 2003. This role provided valuable insights into the development of clinical compounds and FDA-approved drugs, further enhancing their capability in managing intellectual property related to biopharmaceuticals.